8:00 AM

6:45 AM

9:40 AM

H. Lee Moffitt Cancer Center and Research InstituteChanning Judith Paller, MD—Chair

The Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPeter Hoskin, MD, FRCP, FRCR

Welcome of the Day

ABSTRACT 308: Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials.

First Author: Shuang Zhao, MD

ABSTRACT 309: Radical prostatectomy (RP) versus radiotherapy (RT) in high-risk prostate cancer (HR-PCa): Emulated randomized comparison with individual patient data (IPD) from two phase III randomized trials (RCTs).

First Author: Soumyajit Roy, MBBS

Edwin Posadas, MD, FACP

Cedars-Sinai Medical Center

Discussion

ABSTRACT LBA18: Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.

First Author: Neeraj Agarwal, MD, FASCO

ABSTRACT 20: Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD).

First Author: David John Fisher, MSc

Tanya B. Dorff, MD

City of Hope Comprehensive Cancer Center

Discussion

Panel Question and Answer

University Hospitals Seidman Cancer Center and Case Western Reserve UniversityDevaki Shilpa Surasi, MBBS—Chair

University of Texas at MD Anderson Cancer Center

PSMA-Based Therapy in Advanced Disease: Touching on Combination SequencingWilliam Kevin Kelly, DO

Thomas Jefferson University Hospital

Beyond PSMA-Targeted Agents for Advanced Disease

Danny Mena Cortes

Nuclear Medicine World

Seeing Is Believing: Radiographic Criteria to Assess Response

ABSTRACT 17: Overall survival and quality of life with [¹⁷⁷Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901).

First Author: Louise Emmett, MD, FRACP, MBChB

ABSTRACT 16: Association of baseline and on-treatment ctDNA fraction with clinical outcomes in patients with mCRPC in the PSMAfore study of ¹⁷⁷Lu-PSMA-617.

First Author: Johann S. De Bono, MD, PhD, MB, FRCP

Panel Question and Answer

With Complimentary Boxed Lunch

With Complimentary Boxed Lunch

University of Oklahoma College of MedicineBarbara Jereczek-Fossa, MD—Chair

IEO European Institute of Oncology IRCCSMichael Cookson, MD, MMHC, FACS

University of Oklahoma College of Medicine

Recurrence After Radiation Therapy: Evaluation, Management, and Outcomes

Heather H. Cheng, MD, PhD

University of Washington

Medical Oncology

Juanita Crook, FRCPC

The University of British Columbia

Radiation Oncology

Thomas Polascik, MD

Duke University Division of Urologic Surgery

Urology (Ablative Focal)

Ashley Ross, MD, PhD

Northwestern University Feinberg School of Medicine

Urology (Salvage Surgery)

Alicia K. Morgans, MD, MPH, FASCO

Dana-Farber Cancer Institute

The Impact of Salvage Therapies: Functional Outcomes and Quality of Life

Panel Question and Answer

Mount Vernon Cancer Centre, University College London, and University of Manchester

Introduction of Dr. DahutWilliam L. Dahut, MD

American Cancer Society

Creative Innovation: Driving Science to Improve Patient-Centered CareQuestion and Answer

3:30 PM

4:45 PM

The University of Texas MD Anderson Cancer CenterNicholas David James—Chair

Institute of Cancer Research, The Royal Marsden Hospital NHS Foundation TrustABSTRACT 15: World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration.

First Author: Chad Tang, MD, BS, MS

Kenneth L. Gage, MD, PhD

H. Lee Moffitt Cancer Center and Research Institute

Radiology

Brandon A. Mahal, MD

University of Miami

Radiation Oncology

Kasmintan A. Schrader, PhD, MBBS

BC Cancer

Genetics

Sandy Srinivas, MD

Stanford School of Medicine

Medical Oncology

Panel Question and Answer

5:45 PM

Hôpital Charles-LeMoyneABSTRACT 310: Impact of testosterone recovery after androgen deprivation therapy on overall survival in patients with high-risk prostate cancer: Long-term data from a phase III trial. – 5 minutes

First Author: Abdenour Nabid, MDABSTRACT 311: Gut health and prostate cancer: The influence of a specific phytochemical-rich food capsule plus or minus a probiotic/prebiotic blend on symptoms and progression—A randomised, double-blind placebo-controlled trial. – 5 minutes

First Author: Robert J. Thomas, MD

ABSTRACT 312: A high omega-3, low omega-6 diet with fish oil for men with prostate cancer on active surveillance: The CAPFISH-3 randomized clinical trial. – 5 minutes

First Author: William Aronson, MD

ABSTRACT 21: Transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT): Efficacy and safety of combining with androgen receptor pathway inhibitors (ARPIs) in metastatic (M1) prostate cancer—Randomised comparison from the STAMPEDE trial platform. – 5 minutes

First Author: Nicholas David James, PhD, FRCP, MBBS

ABSTRACT 22: Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: A randomized phase II trial (GROUQ-PCS 9). – 5 minutes

First Author: Tamim Niazi, MD

ABSTRACT LBA138: Mevrometostat (PF-06821497), an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC): A randomized dose-expansion study. – 5 minutes

First Author: Michael Thomas Schweizer, MD

Panel Question and Answer

With Complimentary Wine and Cheese Reception

With Complimentary Wine and Cheese Reception

Hôpital Charles-LeMoyne

Poster Walk LeaderChanning Judith Paller, MD

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Poster Walk Leader

6:45 PM

Florida Cancer Specialists & Research InstituteNicholas I. Simon, MD, MSc—Chair

National Cancer InstituteAndrea B Apolo, MD

Welcome of the Day

ABSTRACT 658: Adjuvant nivolumab (NIVO) vs placebo (PBO) for high-risk muscle-invasive urothelial carcinoma (MIUC): Additional efficacy outcomes including overall survival (OS) in patients (pts) with muscle-invasive bladder cancer (MIBC) from CheckMate 274.

First Author: Matthew I. Milowsky, MD, FASCO

ABSTRACT 659: Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. – 10 minutes

First Author: Matthew D. Galsky, MD, FASCO

Elizabeth R. Plimack, MD, FASCO, MS

Fox Chase Cancer Center, Temple Health

Discussion

ABSTRACT 661: Safety and efficacy of neoadjuvant immunotherapy with durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (gemcitabine/cisplatin or carboplatin) in patients with operable high-risk upper tract urothelial carcinoma. – 10 minutes

First Author: Nadine Houede, MD

ABSTRACT 665: Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial. – 10 minutes

First Author: Xinan Sheng, MD

Scot Anthony Niglio, MD, MS

National Institutes of Health Division of Occupational Health and Safety

Discussion

Panel Question and Answer

Springfield ClinicBogdana Schmidt, MD, MPH—Chair

University of Utah

The Changing World of Non-Muscle Invasive Bladder CancerCase Presentation

Girish S. Kulkarni, MD, PhD

Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network

Urology

Mark Tyson, MPH

Mayo Clinic Arizona

Urology

Tracy L Rose, MD

University of North Carolina at Chapel Hill

Medical Oncology

Panel Question and Answer

With Complimentary Boxed Lunch

With Complimentary Boxed Lunch

University of California, San Diego HealthAnja Lorch, MD—Chair

Universitätsspital ZürichNabil Adra, MD

Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center

High-Dose Chemotherapy in Testicular Cancer: Current Evidence and Clinical Indications 

Axel Heidenreich, MD

University Hospital of Cologne

Primary Retroperitoneal Lymph Node Dissection in Stage II Seminoma: Management Strategies and Current Controversies

Darren R. Feldman, MD

Memorial Sloan Kettering Cancer Center

Landscape of New Trials and Targets in Refractory Germ Cell Tumors 

Panel Question and Answer 

Dana-Farber Cancer Institute, Brigham and Women’s HospitalBenjamin Garmezy, MD—Chair

Sarah Cannon Research InstituteDi Maria Jiang, MD, MSc, FRCPC

Princess Margaret Hospital, University Health Network

Targeting Bladder Cancer With Antibody Drug Conjugates

Funda Meric-Bernstam, MD, FASCO

University of Texas MD Anderson Cancer Center

HER2 Antibody-Drug Conjugate Therapy: A New Frontier in Bladder Cancer

Daniel Castellano, MD

Servicio de Oncología Médica, Hospital Universitario 12 de Octubre

Overcoming Challenges of Antibody-Drug Conjugate Toxicity in Bladder Cancer

Terence W. Friedlander, MD

University of California, San Francisco Medical Center

Better Together? Exploring Novel Drug Combinations With Antibody-Drug Conjugates

ABSTRACT 657: Nectin-4 targeted ADC, SHR-A2102, in patients with advanced or metastatic urothelial carcinoma: A phase 1 study.

First Author: Bixia Tang, MD, PhD

Panel Question and Answer

Barts Cancer CentreJoaquim Bellmunt, MD—Chair

Dana-Farber Cancer InstituteRoger Li, MD

H. Lee Moffitt Cancer Center and Research Institute

Capturing What You Cannot See: How Can ctDNA Be Used to Improve Clinical Staging for Upper Tract Disease?

Alexander William Wyatt, PhD

Vancouver Prostate Centre, University of British Columbia

Evolution of Ctdna Detection with Next Generation Technology

Nimira S. Alimohamed, FRCPC

Arthur Child Comprehensive Cancer Centre, University of Calgary

Potential Impact of ctDNA on Perioperative Management of Muscle-Invasive Bladder Cancer

Gillian Vandekerkhove, PhD, MSc

Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia

Beneath the Surface: Unleashing the Potential of Ctdna across the Spectrum of Urothelial Carcinoma

Panel Question and Answer

Department of Urology, NYU Langone HealthABSTRACT 662: A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1.

First Author: Gopa Iyer, MDABSTRACT 663: Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study.

First Author: Funda Meric-Bernstam, MD, FASCO

ABSTRACT 664: EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).

First Author: Thomas Powles, MD, PhD, FCRP

ABSTRACT 666: Clinically advanced urothelial bladder cancer (CAUBC) in young onset bladder cancer (YOUC) patients: A genomic landscape study.

First Author: Alina Basnet, MD, MBBS

ABSTRACT 667: A phase 1/2 trial of durvalumab plus intravesical gemcitabine and docetaxel in BCG-unresponsive non-muscle invasive bladder cancer patients (HCRN GU16-243: ADAPT-BLADDER Cohort 4).

First Author: Noah M. Hahn, MD

ABSTRACT 815: A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2).

First Author: Pooja Ghatalia, MD

Panel Question and Answer

With Complimentary Wine and Cheese Reception

With Complimentary Wine and Cheese Reception

National Cancer Institute

Poster Walk LeaderArmine Smith, MD

Johns Hopkins University School of Medicine

Poster Walk Leader

University of California, San FranciscoDaniel Shapiro—Chair

University of Wisconsin-MadisonTodd Matthew Morgan, MD

Welcome of the Day

ABSTRACT 438: Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313.

First Author: Laurence Albiges, MD, PhD

ABSTRACT 439: Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial.

First Author: Robert J. Motzer, MD

ABSTRACT 440: KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and targeted therapy combinations for advanced clear cell renal cell carcinoma (ccRCC).

First Author: Katy Beckermann, MD, PhD

Tian Zhang, MD, MHS

UT Southwestern University

Discussion

ABSTRACT 618: Prospective COTRIMS (Cologne trial of retroperitoneal lymphadectomy in metastatic seminoma) trial: Final results.

First Author: Axel Heidenreich, MD

Clint Cary, MD, MBA, MPH

Indiana University Simon Comprehensive Cancer Center

Discussion

Panel Question and Answer

University of California, Davis Comprehensive Cancer CenterAxel Bex, MD, PhD—Chair

Royal Free London NHS Foundation TrustABSTRACT 437: Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214.

First Author: Wenxin Xu, MD

Simpa Samuel Salami, MD, MPH

University of Michigan

Biomarkers in Renal Cell Carcinoma: Dead End or Turning Point?

Samra Turajlic, MD, PhD

The Francis Crick Institute

The Future of Biomarkers in Renal Cell Carcinoma

Laurence Albiges, MD, PhD

Gustave Roussy, Université Paris Saclay

Adjuvant Therapy in Renal Cell Cancer: A Practical Guide

Panel Question and Answer

With Complimentary Boxed Lunch

With Complimentary Boxed Lunch

University of Texas MD Anderson Cancer Center

Poster Walk LeaderShuchi Gulati, MD, FACP, MS

UC Davis Comprehensive Cancer Center

Poster Walk Leader

​​​​​​​1:30 PM

University of Texas MD Anderson Cancer CenterABSTRACT 441: Casdatifan (Cas) monotherapy in patients (pts) with previously treated clear cell renal cell carcinoma (ccRCC): Safety, efficacy and subgroup analysis across multiple doses from ARC-20, a phase 1 open-label study.

First Author: Toni K. Choueiri, MD, FASCOABSTRACT 442: Racial disparities in renal cell carcinoma histology and outcomes: Insights from the French Kidney Cancer Research Network (UroCCR-191).

First Author: Xiaofan Lu, PhD

ABSTRACT 443: Lenvatinib plus tislelizumab as first-line therapy for advanced fumarate hydratase-deficient renal cell carcinoma: A single-center, single-arm, phase II study.

First Author: Wen Kong, PhD

ABSTRACT 444: Final overall survival and new ctDNA analysis in MET-driven advanced papillary renal cancer (CALYPSO).

First Author: Francesca Jackson-Spence, MBChB

ABSTRACT 1: EPIC-A: Phase II trial of cemiplimab plus standard of care chemotherapy followed by maintenance cemiplimab in locally advanced or metastatic penile carcinoma.

First Author: Amit Bahl, MD, FRCP, FRCR

Panel Question and Answer

Cedars-Sinai Medical CenterKathryn Hacker Gessner, MD, PhD—Chair

UNC School of MedicineMaria T. Bourlon, MD, MSc, FASCO

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

Medical Oncology

Matthew T Campbell, MD, MS

The University of Texas MD Anderson Cancer Center

Medical Oncology

Raquibul Hannan, MD, PhD

University of Texas Southwestern Medical Center

Radiation Oncology

Viraj A. Master, MD, PhD

Emory School of Medicine

Urology

Panel Question and Answer